Day: November 4, 2025

Following the announcement of its share buyback programme on 30 October 2025, Ayvens has repurchased EUR 275 million of its own shares as part of the sell down of c. EUR 940 million by the Lincoln Consortium1 which was executed through an accelerated bookbuilding on 3 November 2025 after market close. This repurchase represents 3.1% of the Group’s share capital and 76% of its total EUR 360 million share buyback programme.   In accordance with the purpose of the share buyback programme2, the shares bought back will be cancelled pursuant to the authorization granted by Ayvens’ combined General Shareholders’ Meeting on 19 May 2025.About AyvensAyvens is a leading global sustainable mobility player committed to making life flow better. We’ve been improving mobility for decades, providing full-service leasing, flexible subscription...

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line with the company’s development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of the company’s phase 2 study with sevuparin in patients with chronic kidney disease with anemia. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated. ”This regulatory approval...

In October 2025, AS Tallink Grupp transported 467,279 passengers, which is a 2.5% decrease compared to October 2024. The number of cargo units decreased by 10.2% to 21,855 units and the number of passenger vehicles decreased by 2.6% to 58,006 units compared to the same period a year ago. AS Tallink Grupp passenger, cargo unit and passenger vehicle numbers for October 2025 were the following:  October 2025 October 2024 ChangePassengers 467,279 479,232 -2.5%Finland – Sweden 137,011 135,119 1.4%Estonia – Finland 286,552 299,440 -4.3%Estonia – Sweden 43,716 44,673 -2.1%       Cargo Units 21,855 24,346 -10.2%Finland – Sweden 2,698 3,267 -17.4%Estonia – Finland 15,879 17,515 -9.3%Estonia – Sweden 3,278 3,564 -8.0%       Passenger Vehicles 58,006 59,530 -2.6%Finland –...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, Portugal, Nov. 04, 2025 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a leading helium project development company, is pleased to announce that it has signed a definitive agreement (the “Agreement”) with Oscillate plc (“Oscillate”) to supersede the non-binding term sheet announced on September 2, 2025,...

Please see below information about transactions made under the fourth tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the buy-back tranche was announced: 29 October 2025. The duration of the buy-back tranche: 30 October to no later than 2 February 2026. Further information on the tranche can be found in the stock market announcement on its commencement dated 29 October 2025, available here: https://newsweb.oslobors.no/message/658157 From 30 October to 31 October 2025, Equinor ASA has purchased a total of 601.752 own shares at an average price of NOK 241.5536 per share. Overview of transactions:Date Trading venue Aggregated daily volume (number of shares) Daily weighted average share price (NOK) Total daily transaction value (NOK)         30 October OSE 300,142 242.3591 72,742,144.99  CEUX        TQEX               31...

Disclosure of trading in own shares occurred from October 28 to October 31, 2025 Saint-Cloud, November 4, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from October 28 to October 31, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders’ Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation:Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code)ELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 20,000 24.9893 XPARELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 8,900 24.9844 CEUXELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 600 25.0200 TQEXELIS...

Coloplast A/S – Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 million, a DKK 123 million increase from last year. Adjusted3 diluted earnings per share (EPS) before special items increased by 2% to DKK 22.84.• Special items expenses amounted to DKK 469 million, related to profitability improvement initiatives, including the Skin Care divestment, management restructuring and the...